This invention relates generally to the particle analysis field, and more specifically to a new and useful cell sorting and analysis system within the cell sorting field.
With an increased interest in cell-specific drug testing, diagnosis, and other assays, systems that allow for individual cell isolation, identification, and retrieval are becoming more desirable within the field of cellular analysis. Furthermore, with the onset of personalized medicine, low-cost, high fidelity cellular sorting systems are becoming highly desirable. However, preexisting cell capture systems suffer from various shortcomings that prevent widespread adoption for cell-specific testing. For example, flow cytometry requires that the cell be simultaneously identified and sorted, and limits cell observation to a single instance. Flow cytometry fails to allow for multiple analyses of the same cell, and does not permit arbitrary cell subpopulation sorting. Conventional microfluidic devices rely on cell-specific antibodies for cell selection, wherein the antibodies that are bound to the microfluidic device substrate selectively bind to cells expressing the desired antigen. Conventional microfluidic devices fail to allow for subsequent cell removal without cell damage, and only capture the cells expressing the specific antigen; non-expressing cells, which could also be desired, are not captured by these systems. Cellular filters can separate sample components based on size without significant cell damage, but suffer from clogging and do not allow for specific cell identification, isolation, and retrieval.
Thus, there is a need in the cell sorting field to create a new and useful cell capture and analysis system.
The following description of the preferred embodiments of the invention is not intended to limit the invention to these preferred embodiments, but rather to enable any person skilled in the art to make and use this invention.
As shown in
The cell capture system 100 preferably achieves individual cell capture and retention without antibody coated chambers 222, and preferably maintains the viability of the cells throughout isolation, capture, retention, and removal. The cell capture system 100 preferably additionally minimizes clogging. The cell capture system 100 preferably accomplishes this by utilizing suitably sized pores 220 and by leveraging massively parallel flow, such that the cells near the sample inlet 320 preferably experience substantially the same pressure as the cells distal the sample inlet 320 while minimizing the total pressure differential required to flow liquid at high rates through the cell capture system. The variation in pressure felt by cells at the respective ends of the array is preferably less than 50% or 75% of the inlet pressure, but can alternatively be more or less. The sample flow is preferably substantially laminar, but can alternatively have any other suitable flow characteristics. The sample flow path is preferably substantially unidirectional, but can alternatively be bi-directional. Cell sorting and viability maintenance can additionally be accomplished by controlling the sample flow rate through the system, or through any other suitable means.
In operation, the cell capture system 100 preferably receives a sample under positive pressure through the inlet manifold 300. Sample flow through the cell capture system 100 can be additionally or alternatively encouraged by providing negative pressure at the outlet manifold 400. Alternatively, actuation pressure may be cycled in a pulse-width modulation fashion or sinusoidal fashion to provide net actuation pressure, either net positive at the inlet or net negative at the outlet. The sample preferably flows through the inlet manifold 300 to the inlet channel 240, through the chambers 222 and pore channels 224 to the outlet channel 260, and out of the cell capture system 100 through the outlet manifold 400. Cells of a predetermined size are preferably trapped within the chamber 222 as the sample flows through the pores 220, wherein the pore channel 224 dimensions preferably prevent flow of certain cell sizes therethrough. For example, in the variation of the cell capture system 100 configured to capture CTCs, the chambers 222 are preferably dimensioned larger than a CTC, and the pore channels 224 are preferably dimensioned smaller than the CTC.
As shown in
The cell capture system 100 preferably includes one or more arrays 200. More preferably, the cell capture system 100 includes multiple arrays 200 aligned in parallel, such that the outlet channel 260 of a first array 200 is preferably oriented parallel to the inlet channel 240 of an adjacent array 200. The multiple arrays 200 are preferably substantially identical, wherein the pores 220 of the multiple arrays 200 preferably have the same or similar chamber 222 dimensions and pore channel 224 dimensions, the inlet channels 240 preferably have similar lengths and widths, and the outlet channels 260 preferably have similar lengths and widths. However, different arrays 200 within the cell capture system 100 can have different pore 220 characteristics, different inlet channel 240 characteristics, and/or different outlet channel 260 characteristics. For example, a cell capture system 100 can include multiple arrays 200, wherein a first array 200 has pores 220 with a large pore channel 224 width that captures large cells, a second array 200 has pores 220 with a medium pore channel 224 width that captures medium sized cells, and a third array 200 has pores 220 with a small pore channel 224 width that captures small cells.
The multiple arrays 200 are preferably fluidly coupled in parallel by the inlet manifold 300. Alternatively, the multiple arrays 200 can be fluidly coupled in series, as shown in
The pores 220 of the array 200 function to capture and retain cells. More preferably, the pores 220 of the array 200 capture and retain a single cell. The pores 220 preferably include a chamber 222 configured to hold a cell, and a pore channel 224 fluidly connected to the chamber 222. The chamber 222 preferably has a length that prevents cell egress due to crossflow within the inlet channel 240, and a width or a depth that prevents excessive cell movement but allows for the cell to move enough such that the cell does not block the pore channel junction. The end of the pore channel 224 proximal the chamber 222 preferably has a width that prevents the cell of interest 10 from passing through, while permitting smaller sample component (e.g. lysed cells, cellular components, etc.) flow therethrough. The end of the pore channel 224 proximal the chamber 222 is preferably smaller than the diameter of the cell of interest 10, but can have any other suitable dimension.
Each array 200 preferably includes multiple pores 220. For example, an array 200 can include 100, 1000, 10,000, 1,000,000, or any suitable number of pores 220. The pores 220 are preferably fluidly coupled in parallel within the array 200, but can alternatively be fluidly coupled in series within the array 200. The pores 220 are preferably arranged in parallel within the array 200, wherein the longitudinal axes of adjacent pores 220 are preferably parallel. However, the pores 220 can be arranged at an angle to adjacent pores 220 within the array 200. The pores 220 of a given array 200 are preferably substantially similar or identical, with chambers 222 of substantially the same dimension and pore channels 224 of substantially the same dimension. However, a single array 200 can have pores 220 with substantially different chamber 222 and pore channel 224 dimensions, with varying chamber 222 lengths, chamber 222 widths, chamber 222 depths, pore channel 224 lengths, pore channel 224 widths, pore channel 224 depths, number of pore channels 224 per pore 220, number of chambers 222 per pore 220, or pores 220 that vary along any other suitable parameter. For example, an array 200 can have multiple pores 220 arranged in parallel, wherein consecutive pores 220 have decreasing pore channel widths.
The chamber 222 of the pore 220 functions to retain a cell. The chamber 222 is preferably fluidly connected to the inlet channel 240 and the pore channel 224. The chamber 222 preferably has a length and width configured to retain an isolated cell, wherein the chamber 222 is dimensioned to prevent cell egress from the chamber 222 due to inlet channel cross-flow. In one variation, this is achieved by controlling the width to height ratio of chamber 222. The width to height ratio of the chamber 222 is preferably 1, but can alternatively be 1.25, 0.5, or any other suitable ratio. The chamber 222 is preferably configured to retain a single cell and to prevent multiple cell retention. In one variation, the chamber 222 is dimensioned such that the height/width of the chamber 222 prevents a second cell from settling to the end of the chamber 222 proximal the pore channel 224 (e.g. the bottom of the chamber 222), and the length of the chamber 222 prevents a single cell egress from the chamber 222 (e.g. the length is longer than the cell diameter), but encourages egress of a second cell from the chamber 222 (e.g. the length is longer than the cell diameter, but shorter than two cell diameters). However, the chamber 222 can be configured to retain multiple cells. The chamber 222 preferably has a length, width and depth between 5-200 microns, but can alternatively have any suitable dimensions. In one variation, the chamber has a length of 50 micrometers, a width of 50 micrometers, and a height of 50 micrometers. In another variation, the chamber has a length of 25 micrometers, a width of 25 micrometers, and a height of 30 micrometers. The chamber 222 preferably has a substantially constant cross-section, but can alternatively have a tapering cross-section, preferably tapering from the inlet channel 240 to the pore channel 224. The variable cross-section can be the cross-section parallel to the broad face of the substrate 112 and/or the cross-section perpendicular to the longitudinal axis of the chamber 222. In one variation, as shown in
The pore channel 224 of the pore 220 functions to filter out the cell of interest 10 and to allow smaller sample components to flow through. The pore channel 224 is preferably fluidly connected to the chamber 222 and the outlet channel 260. More preferably, the pore channel 224 is fluidly connected to the portion of the chamber 222 distal from the inlet channel 240. The pore channel 224 is preferably substantially straight and linear, but can alternatively be curved. The pore channel 224 preferably has a width smaller than the diameter of the cell of interest 10, such that the pore channel 224 prevents cell passage therethrough. The pore channel 224 preferably has a width and depth between 1-25 microns and a length between 5-500 microns, but can have any other suitable width, depth, and length. In one variation, the pore channel 224 has a width of 7-10 micrometers, a depth of 7-10 micrometers, and a length of 5-50 micrometers. The pore channel 224 preferably has a substantially constant cross-section, but can alternatively have a tapering or variable cross section. The pore channel 224 is preferably aligned with its longitudinal axis parallel the longitudinal axis of the chamber 222. More preferably, the pore channel 224 is coaxial with the chamber 222. However, the pore channel 224 can be aligned at an angle with the chamber 222. Each pore 220 preferably includes a single pore channel 224, but can alternatively include multiple pore channels 224, wherein the multiple pore channels 224 preferably extend in parallel from the end of the respective chamber 222 proximal the outlet channel 260.
The inlet channel 240 of the array 200 functions to receive a volume of the sample and to distribute the sample to the pores 220. The inlet channel 240 preferably fluidly connects the inlet manifold 300 to the chambers 222 of the array 200. The inlet channel 240 preferably includes a first end, a second end, and a channel connecting the first and second ends. The inlet channel 240 is preferably fluidly connected to the inlet manifold 300 at the first end, is fluidly connected to the chambers 222 of the array 200 along the inlet channel 240 length, and is preferably fluidly sealed at the second end. The second end can be sealed by the substrate no or can be sealed by a sealant, such as a self-sealing laminate (e.g. made of rubber, polyethylene, etc.). However, the inlet channel 240 can include a first and/or second valve disposed within the first and/or second end, wherein the valves can operate between an open and a closed state. The body of the inlet channel 240 is preferably defined by the substrate 110, but can alternatively be partially defined by the substrate no, wherein the other portions can be defined by self-sealing laminate or any other suitable sealant. The inlet channel 240 is preferably arranged such that the inlet channel longitudinal axis is perpendicular to the longitudinal axes of the chambers 222, but can alternatively be arranged at an angle. The chambers 222 preferably extend from a single side of the inlet channel 240, but can alternatively extend from multiple sides (e.g. opposing sides). The inlet channel 240 is preferably substantially straight, but can alternatively be curved or bent. The inlet channel 240 preferably has a substantially constant cross-section, but can alternatively have a variable cross section. The cross-section can be the cross-section parallel to the inlet channel longitudinal axis or perpendicular to the inlet channel longitudinal axis. In one variation, the inlet channel 240 tapers with distance away from the inlet manifold 300. The inlet channel 240 preferably has a depth and width larger than the diameter of the cell of interest 10. The inlet channel 240 preferably a depth and/or width between 5-200 microns, but can alternatively have any suitable depth and/or width. In one variation, the inlet channel has a width of 50-100 micrometers, and a depth of 50-100 micrometers. The inlet channel 240 preferably has a length that can accommodate all the pores 220 of the array 200. In one variation, the inlet channel 240 preferably has a length longer than the combined widths of the chambers 222. In another variation, the inlet channel 240 extends to the edge of the substrate 110. Each array 200 preferably includes one inlet channel 240, but can alternatively include multiple inlet channels 240. For example, an array 200 can include two inlet channels 240 that feed two sets of pores 220 extending from either side of a central outlet channel 260, wherein each inlet channel 240 feeds one set of pores 220. However, the array 200 can include any suitable configuration of inlet channels 240.
The outlet channel 260 of the array 200 functions to receive a volume of the sample and to distribute the sample to the pores 220. The outlet channel 260 preferably includes a first end, a second end, and a channel connecting the first and second ends. The outlet channel 260 is preferably fluidly connected to the outlet manifold 400 at the second end, fluidly connected to the chambers 222 of the array 200 along the outlet channel 260 length, and is preferably fluidly sealed at the first end. The first end of the outlet channel 260 can be sealed by the substrate no or can be sealed by a sealant, such as a self-sealing laminate (e.g. made of rubber, polyethylene, etc.). Alternatively, the outlet channel 260 can include a first and/or second valve disposed within the first and/or second end, wherein the valves can operate between an open and a closed state. The body of the outlet channel 260 is preferably defined by the substrate 110, but can alternatively be partially defined by the substrate no, wherein the other portions can be defined by self-sealing laminate or any other suitable sealant. The outlet channel 260 is preferably arranged such that the outlet channel longitudinal axis is perpendicular to the longitudinal axes of the chambers 222, but can alternatively be arranged at an angle. The chambers 222 preferably extend from a single side of the outlet channel 260, but can alternatively extend from multiple sides (e.g. opposing sides). The outlet channel 260 is preferably substantially straight, but can alternatively be curved or bent. The outlet channel 260 preferably has a substantially constant cross-section, but can alternatively have a variable cross section. The outlet channel 260 cross-section can be the cross-section parallel outlet channel longitudinal axis or perpendicular the outlet channel longitudinal axis. In one variation, the outlet channel 260 tapers with distance away from the outlet manifold 400. The outlet channel 260 preferably has a depth and width similar to that of the inlet channel 240, but can alternatively have a depth and width smaller or larger than that of the inlet channel 240. The outlet channel 260 preferably a depth and/or width between 5-200 microns, but can alternatively have any suitable depth and/or width. In one variation, the outlet channel has a width of 50-100 micrometers, and a depth of 50-100 micrometers. The outlet channel 260 preferably has a length that can accommodate all the pores 220 of the array 200. In one variation, the outlet channel 260 preferably has a length longer than the combined widths of the chambers 222. In another variation, the outlet channel 260 extends to the edge of the substrate no. Each array 200 preferably includes one outlet channel 260, but can alternatively include multiple outlet channels 260. For example, an array 200 can include two outlet channels 260 that egress two sets of pores 220 extending from either side of a central inlet channel 240, wherein each outlet channel 260 egresses one set of pores 220.
The inlet manifold 300 of the cell capture system 100 functions to receive a sample and to distribute the sample to the arrays 200. More preferably, the inlet manifold 300 distributes the sample to an inlet channel 240 of an array 200. The inlet manifold 300 preferably additionally includes an inlet 320, wherein the inlet manifold 300 receives the sample from the inlet 320. The inlet manifold 300 preferably provides a substantially linear flow path from the inlet 320 to the inlet channels 240 while substantially minimizing the differences in pressure experienced by different arrays 200 within the system. The inlet manifold 300 is preferably defined within the same substrate broad face as the array 200, but can alternatively be defined through a portion or the entirety of the substrate thickness. The entirety of the inlet manifold 300, except for the inlet 320, is preferably fluidly sealed by the top layer 120.
In one variation, as shown in
In another variation, as shown in
In one variation, the cell capture system 100 includes an inlet manifold 300 with one inlet sub-manifold tier, wherein the inlet sub-manifold 302 includes multiple feeder channels 206, each feeder channel independently fluidly connected to a inlet channel 240 of an array 200.
In another variation, the cell capture system 100 includes an inlet manifold 300 including two tiers of inlet sub-manifolds 302 (as shown in
The inlet 320 of the inlet manifold 300 functions to provide a fluid connection between the cell capture system 100 exterior and interior. More preferably, the inlet 320 provides a fluid connection between the cell capture system 100 exterior and the inlet manifold 300. The cell capture system 100 preferably includes one inlet 320, but can alternatively include multiple inlets 320. Each inlet 320 is preferably fluidly connected to one inlet manifold 300 through a fluid connection (e.g. a channel), but can alternatively be connected to multiple inlet manifolds 300. Each inlet manifold 300 is preferably fluidly connected to one inlet 320, but can alternatively be connected to multiple inlets 320. The longitudinal axis of the inlet 320 is preferably normal to the longitudinal axis of the main channel 204 of the inlet manifold 300, but can alternatively be parallel. The longitudinal axis of the inlet 320 is preferably normal to the broad face of the substrate 112, but can alternatively be parallel to the broad face of the substrate 112, at an angle to the broad face of the substrate 112, or arranged in any suitable manner. In one variation of the cell capture system 100, the inlet 320 is a hole or aperture through a portion of the substrate thickness, extending from a broad face of the substrate 112 to the plane defining the inlet manifold 300. The broad face of the substrate 112 from which the inlet 320 extends can either be the broad face on which the inlet manifold 300 is defined, wherein a fluid connection connecting the inlet 320 and the inlet manifold 300 is also defined on the same broad face, or can be the broad face opposite that on which the inlet manifold is defined 114, wherein the inlet 320 extends through substantially the whole of the substrate thickness to connect with the inlet manifold 300. In another variation of the cell capture system 100, the inlet 320 is a hole or aperture through a side of the substrate 110, wherein the inlet 320 extends in parallel with a broad face of the substrate 112 towards the inlet manifold 300. In this variation, a fluid connection normal to the broad face of the substrate 112 preferably connects the inlet 320 with the inlet manifold 300. However, any suitable configuration of the inlet 320 can be used.
The outlet manifold 400 of the cell capture system 100 functions to receive filtered sample and to egress the filtered sample from the cell capture system 100. More preferably, the outlet manifold 400 receives the filtered sample from an outlet channel 260 of an array 200. The outlet manifold 400 preferably additionally includes an outlet 420, wherein the outlet manifold 400 egresses the filtered sample from the outlet 420. The outlet manifold 400 preferably provides a substantially linear flow path from the outlet channels 260 to the outlet 420, but can alternatively provide a tortuous flow path. The outlet manifold 400 is preferably defined within the same substrate broad face as the array 200, but can alternatively be defined through a portion or the entirety of the substrate thickness, on the opposing broad face of the substrate 112, or on any suitable portion of the substrate no. The entirety of the outlet manifold 400, except for the outlet 420, is preferably fluidly sealed by the top layer 120.
In one variation, as shown in
In another variation, as shown in
In one variation, the cell capture system 100 includes an outlet manifold 400 with one outlet sub-manifold tier, wherein the outlet sub-manifold 402 includes multiple feeder channels 206, each feeder channel independently fluidly connected to a outlet channel 260 of an array 200.
In another variation, the cell capture system 100 includes an outlet manifold 400 including two tiers of outlet sub-manifolds 402, wherein the feeder channels 206 of the first tier are fluidly connected to the main channels 204 of the second tier, and the feeder channels 206 of the second tier are fluidly connected to the outlet channels 260. The first tier preferably includes one outlet sub-manifold 402, with one main channel 204 and multiple feeder channels 206. The second tier preferably includes multiple outlet sub-manifolds 402, wherein each second tier outlet sub-manifold 402 is fluidly connected to a first tier feeder channel and a subset of the arrays 200 of the cell capture system 100. For example, a second tier outlet sub-manifold 402 can be fluidly connected to four outlet channels 260 of a forty-array 200 cell capture system 100, wherein the second tier outlet sub-manifold 402 includes one main channel 204 and four feeder channels 206, each feeder channel independently fluidly connected to an outlet channel 260. In this variation, the first tier main channel 204 preferably has a larger width and/or height than the second tier main channels 204, and the first tier feeder channels 206 preferably have a larger width and/or height than the second tier feeder channels 206. The second tier feeder channels 206 are preferably substantially the same width and/or height as the outlet channels 260, but can alternatively have different dimensions than the outlet channels 260. In another variation, the outlet manifold 400 includes three tiers of branching outlet sub-manifolds 402. In another variation, the outlet manifold 400 includes the same number of tiers as the inlet manifold 300. However, the outlet manifold 400 can include any suitable number of outlet sub-manifold tiers.
The outlet 420 of the outlet manifold 400 functions to provide a fluid connection between the cell capture system 100 interior and the cell capture system 100 exterior. More preferably, the outlet 420 provides a fluid connection between the cell capture system 100 exterior and the outlet manifold 400. The cell capture system 100 preferably includes one outlet 420, but can alternatively include multiple outlets 420. Each outlet 420 is preferably fluidly connected to one outlet manifold 400 through a fluid connection (e.g. a channel), but can alternatively be connected to multiple outlet manifolds 400. Each outlet manifold 400 is preferably fluidly connected to one outlet 420, but can alternatively be connected to multiple outlets 420. The longitudinal axis of the outlet 420 is preferably normal to the longitudinal axis of the main channel 204 of the outlet manifold 400, but can alternatively be parallel. The longitudinal axis of the outlet 420 is preferably normal to the broad face of the substrate 112, but can alternatively be parallel to the broad face of the substrate 112, at an angle to the broad face of the substrate 112, or arranged in any suitable manner. In one variation of the cell capture system 100, the outlet 420 is a hole or aperture through a portion of the substrate thickness, extending from a broad face of the substrate 112 to the plane defining the outlet manifold 400. The broad face of the substrate 112 from which the outlet 420 extends can either be the broad face on which the outlet manifold 400 is defined, wherein a fluid connection connecting the outlet 420 and the outlet manifold 400 is also defined on the same broad face, or the broad face opposite that on which the outlet manifold is defined 114, wherein the outlet 420 extends through substantially the whole of the substrate thickness to connect with the outlet manifold 400. When the inlet 320 is defined on a broad face of the substrate 112, the outlet 420 is preferably defined on the same broad face as the inlet 320, but can alternatively be defined on the opposing broad face. In another variation of the cell capture system 100, the outlet 420 is a hole or aperture through a side of the substrate no, wherein the outlet 420 extends in parallel with a broad face of the substrate 112 towards the outlet manifold 400. In this variation, a fluid connection normal to the broad face of the substrate 112 preferably connects the outlet 420 with the outlet manifold 400. When the inlet 320 is also defined on a side of the substrate no, the outlet 420 is preferably defined on a side of the substrate opposing the side defining the inlet 320. However, the outlet 420 can alternatively be defined on the same side or an adjacent side. However, any suitable configuration of the outlet 420 can be used.
The cell capture system 100 can additionally include an isolation mechanism 500 that functions to isolate cells within individual pores 220. In one variation, the isolation mechanism 500 includes an isolation inlet 520 and an isolation outlet 540, fluidly connected to an array 200, that functions to permit isolation material ingress and egress, respectively. Both the isolation inlet 520 and the isolation outlet 540 are preferably fluidly connected to both the inlet channel 240 and the outlet channel 260. In one variation, as shown in
The isolation material preferably isolates a pore 220 within an array 200. The isolation material preferably has a flow state and a set state, wherein a photochemical reaction, thermochemical reaction, polymerization reaction or any other suitable reaction switches the isolation material from the flow state to the set state. In the flow state, the isolation material is preferably substantially viscous, such that the isolation material does not flow into the pores 220 during introduction into the cell capture system 100. In the set state, the isolation material is preferably a solid or gel that prevents cell egress from the pore 220, and is preferably porous or selectively permeable to permit buffer and reagent penetration therethrough. The isolation material is preferably a photopolymerizable hydrogel, such as PEG or polyacrylamide with photoinitiator, but can alternatively be any suitable material with any other suitable polymerization agent. In one variation, the isolation layer may be an immiscible liquid such as oil. In another variation, select portions of the isolation material can be reacted to seal specific pores 220. For example, as shown in
The cell capture system 100 can additionally include optical elements 130 that function to facilitate imaging. The optical elements 130 function to adjust incoming light, preferably to facilitate better imaging. The optical elements 130 can function to bend, reflect, collimate, focus, reject, or otherwise adjust the incoming light. The optical elements 130 are preferably fabricated within the same process as the cell capture system 100 manufacture, but can alternatively be included after cell capture system 100 manufacture. The optical elements 130 are preferably defined within the substrate no, but can alternatively be defined by the top layer 120 or by a separate component. Optical elements 130 can include light reflectors disposed within the substrate thickness adjacent the arrays 200 (as shown in
The cell capture system 100 can additionally include pore affinity mechanisms that function to attract a cell of interest 10 towards a chamber of the chambers 222. Pore affinity mechanisms can include electric field traps, features within the inlet channel 240 that direct flow into a pore 220, negative pressure application to the outlet channel 260, or any other suitable pore affinity mechanism.
The cell capture system 100 is preferably defined on a substrate 110. More preferably, the cell capture system 100 is defined on a single broad face of a substrate 112, wherein the array 200, including the inlet channel 240, pores 220, and outlet channel 260, is preferably defined on a single broad face of the substrate 112. More preferably, the array 200, inlet manifold 300, and outlet manifold 400 are all defined on the same broad face. Thus, sample flow through the cell capture system 100 preferably runs substantially parallel to the broad face of the substrate 112. The array 200, inlet manifold 300, and outlet manifold 400 are all preferably defined by recesses in the broad face of the substrate 112, but can alternatively be channels defined by walls that are built on top of the substrate no, or defined in any other suitable manner. The substrate no preferably defines a portion of the cell capture system 100 (e.g. three walls of the system), wherein the remaining portions (e.g. one wall) are preferably defined by a top layer 120. The top layer 120 preferably forms a substantially fluid impermeable seal with the substrate no to fluidly seal the cell capture system 100. Alternatively, the cell capture system 100 can be defined through the thickness of the substrate no, wherein the inlet channel 240 is defined on a first broad face of the substrate 112, the outlet channel 260 is defined on an opposing broad face of the substrate 112, and the pores 220 are defined through the thickness of the substrate no.
The substrate no is preferably optically transparent, biocompatible, and substantially inert. Examples of material that can be used for the substrate no include glass, high refractive index polymer, or any other suitable optically transparent material; silicon; any suitable polymer such as polyethlyene, polypropylene, polycarbonate, acrylic, or silicone; quartz, glass, metals, ceramics, or any other suitable material. The top layer 120 is preferably an optically clear layer that is laminated, adhered, heat-bonded, laser-bonded, anodic bonded, or otherwise joined to the substrate no. The top layer 120 is preferably a polymeric laminate, but can alternatively be a glass cover slip or any other suitable top layer 120.
The cell capture system 100 is preferably manufactured through microfabrication processes, but can alternatively be manufactured through injection molding, a combination of microfabrication (e.g. to create masters) and injection molding (e.g. for bulk manufacturing), a combination of microfabrication (e.g. to create masters) and hot embossing (e.g. for bulk manufacturing), laser etching, CNC, or any other suitable manufacturing process. Microfabrication techniques that can be used include photolithography, DRIE, wet etching, and anodic bonding, but any suitable microfabrication technique can be used. The arrays 200, inlet manifold 300 and outlet manifold 400 are preferably formed within a single manufacturing process, but can alternatively formed through multiple sequential or interrupted processes. The inlet 320 and outlet 420 can additionally be formed within the same process as that of the arrays 200, inlet manifold 300, and outlet manifold 400, but can alternatively be formed before or after using different processes.
In one variation, as shown in
In another variation, as shown in
In a first example, as shown in
In a second example, as shown in
In a third example, as shown in
In a fourth example, as shown in
In a fifth example, as shown in
In a sixth example, as shown in
Cell Removal
The cell capture system 100 is configured to facilitate selective cell removal from known, addressable locations. While an individual cell from a single pore 220 is preferably selectively removed, the system can facilitate simultaneous multiple cell removal from a single array 200 or a subset of arrays 200. The cell is preferably removed by applying a removal force to the cell. The removal force is preferably applied by pumping fluid through the pore channel 224 into the chamber 222, but can alternatively be applied by aspirating the contents out of the chamber 222. In one variation, the pump pressure provided by a pump mechanism at the cell capture system 100 outlet 420 is less than 10,000 Pa. In one specific variation, the provided pump pressure is 6,000 Pa. However, any other suitable pump or aspiration pressure can be used.
In a first variation of the cell removal method, one or more cells can be removed from the cell capture system 100 by ingressing a purging fluid through an outlet manifold 400 and collecting flushed-out cells at the inlet 320 (backflowing the cells). This can be particularly desirable when collection of cells from multiple fluidly linked sites is desired. Cell capture system 100s including multiple outlet manifolds 400 (e.g. systems with one outlet manifold 400 per array 200) can be particularly suited to this cell removal method, as the cells within a given array 200 can be removed without affecting adjacent captured cells within other arrays 200 by only ingressing fluid through the outlet manifold 400 directly connected to the selected array 200. Alternatively, cell capture system 100s with multiple tiers of sub-manifolds can be suited to this cell removal method, wherein cells retained within a subset of arrays 200 that are fluidly connected by sub-manifold can be simultaneously removed. However, any suitable cell capture system 100 configuration can be utilized with this cell removal method.
In a second variation of the cell removal method, cell removal can be achieved by utilizing a cell removal tool 600. The cell removal tool 600 of the cell capture system 100 functions to selectively remove one or more isolated cells from an addressable location within the cell capture system 100. The cell removal tool 600 is preferably configured to remove a cell from a single chamber 222, but can alternatively be configured to simultaneously remove multiple cells from multiple chambers 222.
In a first variation of the cell removal tool, the cell removal tool 600 is configured to puncture the top layer 120 from a direction normal to the broad face of the substrate 112. The cell removal tool 600 preferably removes the cell in a substantially normal direction from the broad face of the substrate 112, but can alternatively remove the cell in an angled direction relative to the broad face of the substrate 112. The cell removal tool 600 preferably includes a hollow needle that punctures the top layer 120 and defines a substantially fluidly isolated volume in fluid communication with one or more pores 220 (e.g. the desired number of pores 220). As shown in
The hollow needle is preferably configured to form a substantially fluidly isolated volume within a pore chamber 222 of interest or a segment of the inlet channel 240 adjacent a pore chamber 222 of interest. A low-pressure generator (e.g. a pump) is preferably then used to aspirate the retained cell out of the pore chamber 222, through the hollow needle, and into the cell collection volume.
The hollow needle is preferably manufactured using microfabrication techniques, but can alternatively be injection molded, laser cut, stamped, or manufactured using any other suitable manufacturing technique. In one variation of hollow needle manufacture, as shown in
In a second variation of the cell removal tool, the cell removal tool 600 is also configured to puncture the top layer 120 from a direction normal to the broad face of the substrate 112. The cell removal tool 600 preferably removes the cell in a substantially normal direction from the broad face of the substrate 112, but can alternatively remove the cell in an angled direction relative to the broad face of the substrate 112. As shown in
In a third variation of the cell removal tool, the cell removal tool 600 is configured to remove one or more cells from the cell capture system 100 in a direction substantially parallel to the broad face of the substrate 112. As shown in
In one variation of cell retrieval tool operation, the cannula preferably traverses through the inlet channel 240 of an array 200 having a cell of interest 10 until the aperture is aligned with the pore 220 containing the cell of interest 10. Fluid can then be ingressed through the associated outlet manifold 400, wherein the pressure of the ingressed fluid pushes the cell of interest 10 out of the pore chamber 222, through the aperture, and into the cannula. Subsequent fluid ingress through the inlet channel 240 can recapture any cells that were backflowed out of their respective pores 220. The cannula can additionally or alternatively include a low-pressure generation mechanism fluidly coupled to the lumen that aspirates the cell out of the pore 220. Alternatively or additionally, the cannula can facilitate cell ingress through capillary action. The cell preferably travels through the lumen and is stored within the cell collection volume.
In this variation of cell retrieval tool operation, the cannula is preferably inserted into the inlet channel 240 through the side of the substrate 110, as shown in
In another variation of cell retrieval tool operation, the cannula includes an aperture through the puncture tip. The cannula is advanced through the inlet channel 240, successively blocking each successive pore chamber 222 until only the desired subset of pores 220 are left uncovered. Fluid can then be provided through the outlet channel 260 directly fluidly connected with the uncovered pores 220 to simultaneously release the cells from the uncovered pores 220, wherein the fluid preferably entrains the cells and moves the cells into the cannula. The cannula can additionally or alternatively be fluidly connected to a low-pressure generator to aspirate the cells into the cell collection volume.
Cell removal from the cell capture system 100 is preferably automated, but can alternatively be semi-automated or manual. In one variation, cell removal is automated, wherein an integrated platform 30 identifies and removes the cells of interest. Cell identification can include automatic fixing, permeabilzation, staining, imaging, and identification of the cells through image analysis (e.g. through visual processing with a processor, by using a light detector, etc.). Cell removal can include advancement of a cell removal tool 600 to the pore 220 containing the cell of interest 10. Cell removal can additionally include cell removal method selection and/or cell removal tool selection. In another variation, cell identification can semi-automated, and cell retrieval can be automated. For example, cell staining and imaging can be done automatically, wherein identification and selection of the cells of interest can be done manually. In another variation, all steps can be performed manually. However, any combination of automated or manual steps can be used.
The cell capture system 100 described above can be used for a variety of biological assays and procedures. Running an assay or procedure preferably includes capturing target cells in addressable locations within the cell capture system and delivering reagents to the interior or surface of each captured cell while maintaining cell registration with its respective pore or location.
In a first example, the cell capture system 100 can be used as a microarray 200, wherein microspheres 140 are introduced into the cell capture system 100 prior to sample introduction. The microspheres 140 are preferably slightly larger than the pore channels 224, but can alternatively be smaller. The microspheres 140 can be coated with specific analytes (e.g. affinity molecules, etc.), wherein the microspheres 140 can create affinity columns within the pores 220. The microspheres 140 can additionally be tagged for imaging. In one variation, multiple sets of microspheres 140 are sequentially introduced into the cell capture system 100, wherein each set of microspheres 140 has an affinity molecule coating different from the other sets. Each microsphere set is preferably tagged with the same imaging tag (e.g. all tagged with Cal Red), but can alternatively be tagged with different imaging tags. Each microsphere set preferably includes a small number of microspheres 140 (e.g. less than the number of pores 220 in the system), but can alternatively have more. The cell capture system 100 is preferably imaged after each microsphere set is introduced to identify the pores 220 occupied by the constituent microspheres 140 of the set. However, the cell capture system 100 can be imaged after all the microspheres 140 are introduced, particularly when each microsphere set is tagged with a different image tag. In this way, a highly multiplexed bead microarrays 200 can be created within the cell capture system 100. In another variation, as shown in
In another example, one or more assays can be run within the cell capture system 100. The cells of interest are preferably first isolated by running the sample through the cell capture system 100. The captured cells are preferably then stained, wherein staining preferably maintains the cell viability. Cell analysis, including morphology and cell counting, is then preferably performed. One or more assays can then be performed on the captured cells. These assays may include Immunocytochemistry, Fluorescence In-situ Hybridization (FISH), Polymerase Chain Reaction (PCR), Enzyme Linked Immunosorbent Assay (ELISA) and other standard cellular and molecular assays known to a person skilled in the art.
Isolating the cells of interest preferably includes pumping the sample through the cell capture system inlet 320 and egressing the remainder of the sample through the cell capture system 100 outlet 420. Isolating the cells of interest can additionally include sample enrichment prior to sample ingress into the cell capture system 100. Isolating the cells of interest can additionally include running a buffer through the cell capture system 100 to rinse the isolated cells. Isolating the cells of interest preferably includes leaving the cells within the pores 220, but can alternatively include cell removal from the cell capture system 100. The removed cells can be passed through a second cell capture system 100 to sequentially enrich the isolated cell population, or can be stored within a cell collection volume for off-chip analysis.
Antibody staining is preferably used to identify the pores 220 that contain the cells of interest. Antibody staining can additionally distinguish the cells of interest over undesired cells 20 of similar size that have also been captured. Antibody staining preferably includes introducing a solution of conjugated antibodies, specific to the cell of interest 10, through the cell capture system 100. The conjugated antibodies are preferably primary antibodies, but can alternatively be secondary antibodies, wherein unconjugated primary antibodies are preferably introduced into the cell capture system 100 prior to conjugated antibody introduction. However, any suitable cell staining method can be used.
Cell analysis is preferably used to determine the morphology of the captured cells and to determine the number and location of captured cells of interest. Cell analysis is preferably performed by an associated integrated platform 30, wherein morphology and cell counting is preferably accomplished through global chip imaging and image analysis. Imaging and analysis is preferably automatically performed, but can alternatively be semi-automated or manually performed. However, morphology determination and cell counting can be achieved through any other suitable method.
Running assays on the isolated cells functions to determine characteristics of the cells and/or determine cell responses to given stimuli. Analyses can be run on the cells individually (e.g. single cell level analysis), wherein cells can be individually fluidly isolated within the cell capture system 100. Alternatively, analyses can be run on the cell capture system 100 as a whole. Alternatively, individual array 200 subsets can be fluidly isolated from other array 200 subsets, wherein different analyses can be performed on different array 200 subsets. Example assays that can be run on the cells include FISH assays, selective cell lysing and lysate collection, single cell molecular analysis (e.g. PCR, RT-PCR, Whole Genome Amplification, ELISPOT, ELISA, Immuno-PCR, etc.), drug testing, cell culturing, affinity analyses, time-responsive analyses, but other analyses can alternatively/additionally be run. Isolated cells can be removed prior to, during, or after the assays have been run, preferably with the cell removal tool 600 but alternatively with any suitable method. Alternatively, isolated cells can be isolated within the chamber 222 (e.g. with an isolation layer), fixed, cultured within the chamber 222, or be retained within the chamber 222 in any other suitable manner.
In one specific example, assaying cells with the cell capture system 100 includes pre-processing a sample containing spiked cancer cells, priming the cell capture system 100, flowing the sample through the cell capture system 100, fixing the cells within their respective pores, and staining the fixed cells. After the assaying procedure, the cells can be manually or automatically imaged and analyzed. The sample is preferably a peripheral whole blood sample, but can be any other suitable sample containing target cells. The cell capture system 100 preferably includes 12,800 pores, but can alternatively include more or less pores. Pre-processing the sample preferably includes diluting the sample (e.g. with a 0.5% formalin in 1×PBS mixture or any other suitable solution containing a fixing agent) and incubating the sample, preferably in a rocker (e.g. for 15-30 minutes). Priming the cell capture system 100 preferably includes introducing an initial buffer (e.g. 1% BSA+ 0.1% triton X in 1×PBS) and removing air bubbles from the system 100. Flowing the sample through the cell capture system 100 preferably includes flowing the sample through the system 100 at a pressure of less than 10,000 Pa in less than 10 minutes while minimizing the introduction of air bubbles, but can alternatively include flowing the sample through the system 100 at any suitable pressure in any suitable time frame. Fixing the cells preferably includes post fixing the cells with a fixing agent (e.g. 2% formalin in wash buffer), which can prepare the cells for subsequent antibody staining. Staining the fixed cells can include washing the fixed cells (e.g. with 1% BSA+25 mM EDTA in 1×PBS) and introducing an antibody cocktail containing antibodies specific to the cells of interest (e.g. a primary antibody cocktail including anti-cytokeratin 8/18 or anti-EpCAM that recognize human epithelial cancer cells, CD45 that recognizes leukocytes, and/or nuclear stain Hoescht 33342) into the cell capture system 100. Staining the fixed cells can additionally include incubating the cells (e.g. for 30-45 minutes at room temperature). Staining the cells can additionally include washing the cells with a wash buffer (e.g. 1% BSA+ 25 mM EDTA in IX PBS), introducing a secondary antibody cocktail containing antibodies that bind to the primary antibodies (e.g. a cocktail including Alexa-conjugated anti-CD45, anti-cytokeratin 8/18, and/or anti-EpCAM), and incubating the cells (e.g. at room temperature for 45 minutes). Assaying the cells can additionally include wash steps between each assay step. The cells are preferably washed with a wash buffer including culture media, buffer, metal ion scavengers and/or surfactants (e.g. a wash buffer including 1% BSA and 0.1% triton X in 1×PBS, a wash buffer including EDTA, etc.).
Sample Preparation
The cell capture system 100 is preferably used with a cell-containing sample. The cell-containing sample is preferably a blood sample, but can alternatively be bodily fluid, cells suspended in buffer or culture medium, or any other suitable cell-containing sample.
While the cell-containing sample can be introduced into the cell capture system 100 without any pre-processing, pre-processing can be preferred to increase the efficacy of cell sorting. Sample pre-processing preferably includes sample enrichment to increase the proportion of desired cells 10 within the sample. Sample enrichment preferably includes substantially removing undesired components from the sample before sample ingress into the cell capture system 100. Sample pre-processing can additionally include preparing the sample for downstream processing or processing the sample in any other suitable manner for any suitable application.
In a first variation, sample components that can form obstacles, such as clots, within the cell capture system 100 are preferably removed. For example, in a blood sample, such components can include red blood cells, platelets, and other similar blood components. These components are preferably removed through density gradient centrifugation, wherein the erythrocyte and granulocyte pellet is preferably discarded, and the remainder of the sample retained. However, these components can be removed through filtration, selective lysing, or any other suitable method of removal or inactivation.
In a second variation, undesired cells 20 of substantially the same size as the desired cells 10 are selectively removed. For example, if CTCs are the desired cells 10, then mono-nuclear cells (e.g. PMBCs) are preferably removed. Undesired, similarly-sized cells are preferably removed by negative selection, but can alternatively be removed by other suitable removal methods, such as centrifugation. Negative selection is preferably achieved through immunomagnetic separation of undesired cells, wherein antibody-coated magnetic particles are introduced into the sample. The antibodies coating the magnetic particles are preferably targeted toward antigens expressed by the undesired cells 20 but not expressed by the desired cells 10. For example, if leukocytes are the undesired cells 20, then anti-CD45 can be used. The sample is then passed through a magnetic field, wherein the magnetic particles selectively remove the bound, undesired cells 20 from the sample.
Negative selection can alternatively or additionally be achieved within the cell capture system 100, wherein the cell capture system 100 includes a first stage fluidly connected to a downstream a second stage. The channels of the first stage preferably include affinity molecules (e.g. antibodies) that selectively bind the undesired cells 20, while permitting the desired cells 10 to flow therethrough. The affinity molecules can be introduced as a coating, as affinity molecule-coated microspheres 140, affinity molecule-coated micropillars, affinity molecule-coated microchannels, or introduced in any other suitable manner. The first stage can be a portion of the inlet manifold 300 or a subset of upstream arrays 200, a separate cell capture system 100, or any suitable upstream stage. The first stage preferably includes large pore channel size s, preferably larger than the diameter of the desired cell 10 (e.g. 35-50 micrometers). The second stage preferably selects for the desired cell 10 according to cell size and/or deformability, and preferably does not include any antibodies or cell-binding coatings.
In one variation of sample preparation, as shown in
Integrated Platform
As shown in
The sample workstation 40 preferably includes a pumping system that regulates the sample flow rate through the system to control the shear forces on the cells while providing enough positive pressure to push unwanted cells and fragments through the chambers 222 of the pores 220. In one variation, the pumping system provides a pumping pressure less than 10,000 Pa. More preferably, the pumping system provides a pumping pressure of approximately 6,000 Pa, but can alternatively provide any suitable pumping pressure. The pumping system is preferably capable of handling varying volume inputs, preferably ranging from 100 microliters to tens of milliliters. As shown in
The workstation preferably enables simultaneous processing of multiple samples (e.g. 12, 24, 96 samples, etc.) of blood or any other suitable specimen. As shown in
The integrated platform 30 can additionally include an imaging platform 50. The imaging platform 50 can function to capture images of cells. The digital imaging system can additionally include software that can allow for specific image quantization and reporting in the platform. The imaging platform 50 preferably includes imaging hardware and imaging software. The imaging software preferably controls the imaging hardware, and can additionally process the images. In one variation, the imaging software analyzes a first image to determine addresses of the pores 220 retaining cells of interest, then controls the imaging hardware to individually image and interrogate each identified pore 220. The imaging software can additionally store the location of the cells of interest for further cell processing, such as cell removal or single cell analysis.
The imaging hardware is preferably configured to accept the cell capture system 100, and can additionally accept conventional imaging equipment, such as microscope slides, cell culture plates, or any other suitable imaging equipment. The imaging hardware is preferably capable of auto-focusing the microscope before image capture, but can alternatively take a series of images at multiple focal lengths, use image post-processing to sharpen the image, or utilize any other suitable method to achieve a focused image.
The imaging hardware preferably includes an automated stage 52 that can facilitate self-calibration, cell capture system interrogation, cell capture system 100 agitation, or move the imaging equipment in any other suitable manner. The automated stage 52 can additionally function to align the cell capture system 100 with the objective or field of image. The automated stage 52 can additionally move the cell capture system 100 relative to the cell removal tool 600 to align the cell removal tool 600 aperture with a desired pore 220. The automated stage 52 can additionally move the cell to the sample workstation 40. The automated stage 52 is preferably driven by a motor, but can be driven by any other suitable mechanism.
The automated stage 52 is preferably capable of moving in at least the z-direction, and can additionally move in the x-direction and/or y-direction. In one variation, as shown in
The stage preferably includes a retention mechanism 54 that retains the cell capture system 100 position relative to the rest of the stage. The retention mechanism 54 is preferably further capable of retaining other imaging equipment, such as glass slides or cell culture plates. The retention mechanism 54 can be as a clip that biases the cell capture system 100 against a brace, a recess in a broad face of the stage, or any other suitable retention mechanism 54. The stage preferably accommodates one cell capture system 100 at a time, but can alternatively accommodate multiple cell capture system 100s simultaneously. In one variation, the stage includes a carousel or conveyor tray that includes a plurality of cell capture system 100s, wherein the stage rotates successive cell capture system 100s under the imaging module 56.
The stage can additionally include a thermal control system thermally coupled to the portion of the stage configured to contact the cell capture system 100. The thermal control system can be used to control the cell capture system 100 temperature by heating and/or cooling the cell capture system 100 during assays or reactions. For example, the thermal control system can heat the cell capture system 100 to incubate the cells retained therein, and cool the cell capture system 100 to quench given biochemical reactions. In one variation, the thermal control system includes a single block configured to contact an entire broad face of the cell capture system 100. In another variation, the thermal control system includes multiple sections, each section configured to heat or cool a given portion of the cell capture system 100 broad face. The thermal control system preferably includes electric heaters, but can alternatively include inductive heaters, ceramic heaters, or any other suitable heaters. The thermal control system can include a heat sink, heat pump, heat exchanger, or any other suitable passive or active cooling mechanism. The thermal control system is preferably optically transparent, but can alternatively have any other suitable optical property.
The stage can additionally include a fluidic manifold 42 that interfaces with the inlet 320 and outlet 420 of the cell capture system 100, such that real-time flow through the cell capture system 100 can be visualized.
The imaging hardware preferably additionally includes an imaging module 56 including an imager and an optimized illuminator capable of capturing high-resolution images at multiple predefined locations of the slide and/or global images of the slide. The imaging module 56 is preferably capable of working with various sets of emission and excitation wavelengths, such that the imaging platform 50 can resolve multiple markers (e.g. fluorescent markers, stains, etc.). The illuminator is preferably capable of providing the appropriate illumination and wavelengths for fluorescence resolution, phase contrast microscopy, dark-field microscopy, bright-field microscopy, and/or any other suitable imaging technique. For example, the imaging hardware can include one or more emitters capable of resolving fluorescence dyes such as FAM, Cal Red, Texas Red, Cy5, CY5.5, or any other suitable fluorescence dye used in cell analysis. The imaging module 56 preferably includes an imager that is preferably optically connected to a microscope that magnifies the portion of the cell capture system 100 to be imaged. The imager can be 5 megapixel, 10 megapixel, 20 megapixel, 50 megapixel, 100 megapixel, or any suitable size imager. The imager can be a CCD, CMOS imager, line scanner, or any other suitable imager.
The imaging hardware can additionally include an identifier reader that functions to read and identify imaging equipment identifiers. The imaging hardware can include a barcode reader, a RFID tag reader, a QR code reader, a nearfield communication device, or any other suitable mechanism that can identify a unique identifier located on the imaging equipment (e.g. the cell capture system 100, a microscope slide, etc.). Alternatively or additionally, the imaging module 56 can be used as the identifier reader. In one variation, a given objective lens is placed over the unique identifier to obtain the correct aspect ratio for imaging module 56 imaging. In another variation, the unique identifier can be pieced together from multiple images. However, any other suitable method of obtaining and identifying the unique identifier can be used.
The imaging hardware is preferably controlled by a processor running imaging software, wherein the processor preferably controls stage motion, microscope focus, and image capture, and can additionally control other functions. Imaging hardware control is preferably based on an image taken by the image hardware, but can alternatively be based on signals received from sensors or other portions of the integrated platform 30.
As a person skilled in the art will recognize from the previous detailed description and from the figures and claims, modifications and changes can be made to the preferred embodiments of the invention without departing from the scope of this invention defined in the following claims.
This application is a continuation of U.S. patent application Ser. No. 17/357,287, filed 24 Jun. 2021, which is a continuation of U.S. patent application Ser. No. 17/005,159, filed 27 Aug. 2020, which is a continuation of U.S. patent application Ser. No. 16/929,427, filed 15 Jul. 2020, which is a continuation of U.S. patent application Ser. No. 16/924,492, filed 9 Jul. 2020, which is a continuation of U.S. patent application Ser. No. 16/835,603, filed 31 Mar. 2020, which is a continuation of U.S. patent application Ser. No. 16/679,639, filed 11 Nov. 2019, which is a continuation of U.S. patent application Ser. No. 16/599,704, filed 11 Oct. 2019, which is a continuation of U.S. patent application Ser. No. 16/536,155, filed 8 Aug. 2019, which is a continuation of U.S. patent application Ser. No. 16/513,580, filed 16 Jul. 2019, which is a continuation of U.S. patent application Ser. No. 16/048,104, filed 27 Jul. 2018, which is a continuation of U.S. patent application Ser. No. 15/657,553, filed 24 Jul. 2017, which is a continuation of U.S. patent application Ser. No. 15/333,420, filed 25 Oct. 2016, which is a is a continuation of U.S. patent application Ser. No. 14/607,918, filed 28 Jan. 2015, which is a continuation of U.S. patent application Ser. No. 13/557,510, filed 25 Jul. 2012, and claims the benefit of U.S. Provisional Application Ser. No. 61/513,785 filed on 1 Aug. 2011, which are all incorporated in their entirety by this reference.
Number | Name | Date | Kind |
---|---|---|---|
4475411 | Wellerfors | Oct 1984 | A |
4551435 | Liberti et al. | Nov 1985 | A |
4710635 | Chupp | Dec 1987 | A |
5266269 | Niiyama et al. | Nov 1993 | A |
5281540 | Merkh et al. | Jan 1994 | A |
5491343 | Brooker | Feb 1996 | A |
5541064 | Bacus et al. | Jul 1996 | A |
5547849 | Baer et al. | Aug 1996 | A |
5851488 | Saul et al. | Dec 1998 | A |
5883370 | Walker et al. | Mar 1999 | A |
5888370 | Becker et al. | Mar 1999 | A |
5993630 | Becker et al. | Nov 1999 | A |
5993632 | Becker et al. | Nov 1999 | A |
6016712 | Warden et al. | Jan 2000 | A |
6127177 | Toner et al. | Oct 2000 | A |
6133030 | Bhatia et al. | Oct 2000 | A |
6150180 | Parce et al. | Nov 2000 | A |
6174683 | Hahn | Jan 2001 | B1 |
6221663 | Bhatia et al. | Apr 2001 | B1 |
6228624 | Terstappen | May 2001 | B1 |
6281008 | Komai et al. | Aug 2001 | B1 |
6287832 | Becker et al. | Sep 2001 | B1 |
6365362 | Terstappen et al. | Apr 2002 | B1 |
6410724 | Dejean et al. | Jun 2002 | B1 |
6433134 | Patron et al. | Aug 2002 | B1 |
6468810 | Korpela | Oct 2002 | B1 |
6525997 | Narayanaswami et al. | Feb 2003 | B1 |
6551841 | Wilding et al. | Apr 2003 | B1 |
6563634 | Shimada et al. | May 2003 | B2 |
6613525 | Nelson et al. | Sep 2003 | B2 |
6623983 | Terstappen et al. | Sep 2003 | B1 |
6641708 | Becker et al. | Nov 2003 | B1 |
6645731 | Terstappen et al. | Nov 2003 | B2 |
6692952 | Braff et al. | Feb 2004 | B1 |
6790330 | Gascoyne et al. | Sep 2004 | B2 |
6821484 | Gregersen | Nov 2004 | B1 |
6861259 | Columbus | Mar 2005 | B2 |
6866823 | Wardlaw | Mar 2005 | B2 |
6960449 | Wang et al. | Nov 2005 | B2 |
7008789 | Gambini et al. | Mar 2006 | B2 |
7035170 | Narayanaswami et al. | Apr 2006 | B2 |
7046357 | Weinberger et al. | May 2006 | B2 |
7148492 | Loney et al. | Dec 2006 | B2 |
7172866 | Hahn et al. | Feb 2007 | B2 |
7198901 | Rachlin | Apr 2007 | B1 |
7217520 | Tsinberg et al. | May 2007 | B2 |
7238521 | Hahn et al. | Jul 2007 | B2 |
7248352 | Hamamatsu et al. | Jul 2007 | B2 |
7258990 | Falcovitz-Gerassi et al. | Aug 2007 | B2 |
7266777 | Scott et al. | Sep 2007 | B2 |
7294468 | Bell et al. | Nov 2007 | B2 |
7316897 | Bisconte et al. | Jan 2008 | B2 |
7332288 | Terstappen et al. | Feb 2008 | B2 |
7338760 | Gong et al. | Mar 2008 | B2 |
7354389 | Kureshy et al. | Apr 2008 | B2 |
7439062 | Bhatt et al. | Oct 2008 | B2 |
7449558 | Yao et al. | Nov 2008 | B2 |
7449778 | Sander | Nov 2008 | B2 |
7501283 | Hersch et al. | Mar 2009 | B2 |
7507528 | Albert et al. | Mar 2009 | B2 |
7588672 | Unger et al. | Sep 2009 | B2 |
7595157 | Tsinberg | Sep 2009 | B2 |
7597528 | Rodi | Oct 2009 | B2 |
7604777 | Columbus | Oct 2009 | B2 |
7638464 | Fagnani et al. | Dec 2009 | B2 |
7695956 | Tsinberg et al. | Apr 2010 | B2 |
7704322 | Hansen et al. | Apr 2010 | B2 |
7710563 | Betzig et al. | May 2010 | B2 |
7738320 | Taha | Jun 2010 | B2 |
7763704 | Ding et al. | Jul 2010 | B2 |
7767152 | Stead et al. | Aug 2010 | B2 |
7815863 | Kagan et al. | Oct 2010 | B2 |
7858757 | Hollmann et al. | Dec 2010 | B2 |
7863012 | Rao et al. | Jan 2011 | B2 |
7901950 | Connelly et al. | Mar 2011 | B2 |
7964349 | Bell et al. | Jun 2011 | B2 |
8008032 | Forsyth et al. | Aug 2011 | B2 |
8013298 | Khursheed | Sep 2011 | B2 |
8021614 | Huang et al. | Sep 2011 | B2 |
8062883 | Woudenberg et al. | Nov 2011 | B2 |
8103080 | George et al. | Jan 2012 | B2 |
8105769 | Bell et al. | Jan 2012 | B2 |
8105780 | Su et al. | Jan 2012 | B2 |
8131053 | Ortyn et al. | Mar 2012 | B2 |
8158410 | Tang et al. | Apr 2012 | B2 |
8174698 | Peter et al. | May 2012 | B2 |
8175371 | George et al. | May 2012 | B2 |
8186913 | Toner et al. | May 2012 | B2 |
8211301 | Safar et al. | Jul 2012 | B2 |
8232112 | Willson et al. | Jul 2012 | B2 |
8252517 | Thomas et al. | Aug 2012 | B2 |
8293524 | Ionescu-Zanetti et al. | Oct 2012 | B2 |
8304230 | Toner et al. | Nov 2012 | B2 |
8329422 | Rao et al. | Dec 2012 | B2 |
8372579 | Toner et al. | Feb 2013 | B2 |
8372584 | Shoemaker et al. | Feb 2013 | B2 |
8406498 | Ortyn et al. | Mar 2013 | B2 |
8465916 | Bell et al. | Jun 2013 | B2 |
8628923 | Hamilton et al. | Jan 2014 | B2 |
8658418 | Daridon | Feb 2014 | B2 |
8680025 | Cooney | Mar 2014 | B2 |
8730479 | Ness et al. | May 2014 | B2 |
8765454 | Zhou et al. | Jul 2014 | B2 |
8771609 | Ehben et al. | Jul 2014 | B2 |
8802367 | Taniguchi et al. | Aug 2014 | B2 |
8936945 | Handique et al. | Jan 2015 | B2 |
8986988 | Karnik et al. | Mar 2015 | B2 |
9103754 | Handique et al. | Aug 2015 | B2 |
9110026 | Collins | Aug 2015 | B2 |
9133499 | Di Carlo et al. | Sep 2015 | B2 |
9145540 | Deutsch et al. | Sep 2015 | B1 |
9174216 | Handique et al. | Nov 2015 | B2 |
9188586 | Fan et al. | Nov 2015 | B2 |
9194001 | Brenner | Nov 2015 | B2 |
9200245 | Deutsch et al. | Dec 2015 | B2 |
9201060 | Voldman et al. | Dec 2015 | B2 |
9249459 | Hamilton et al. | Feb 2016 | B2 |
9260753 | Xie et al. | Feb 2016 | B2 |
9290808 | Fodor et al. | Mar 2016 | B2 |
9290809 | Fodor et al. | Mar 2016 | B2 |
9304065 | Fowler et al. | Apr 2016 | B2 |
9315768 | Vrouwe et al. | Apr 2016 | B2 |
9315857 | Fu et al. | Apr 2016 | B2 |
9329170 | Clarke et al. | May 2016 | B2 |
9364829 | Heid et al. | Jun 2016 | B2 |
9410201 | Hindson et al. | Aug 2016 | B2 |
9429500 | Fowler et al. | Aug 2016 | B2 |
9506845 | Fowler et al. | Nov 2016 | B2 |
9507609 | Glazer et al. | Nov 2016 | B2 |
9513195 | Handique et al. | Dec 2016 | B2 |
9567645 | Fan et al. | Feb 2017 | B2 |
9567646 | Fan et al. | Feb 2017 | B2 |
9598736 | Fan et al. | Mar 2017 | B2 |
9610581 | Handique et al. | Apr 2017 | B2 |
9637799 | Fan et al. | May 2017 | B2 |
9701998 | Hindson et al. | Jul 2017 | B2 |
9707562 | Handique et al. | Jul 2017 | B2 |
9708659 | Fodor et al. | Jul 2017 | B2 |
9746413 | Handique et al. | Aug 2017 | B2 |
9752181 | Handique et al. | Sep 2017 | B2 |
9757707 | Husain et al. | Sep 2017 | B2 |
9802193 | Handique et al. | Oct 2017 | B2 |
9840732 | Anderson et al. | Dec 2017 | B2 |
9845502 | Fodor et al. | Dec 2017 | B2 |
9850483 | Clarke et al. | Dec 2017 | B2 |
9952126 | Fowler et al. | Apr 2018 | B2 |
9995662 | Husain et al. | Jun 2018 | B2 |
10376889 | Masquelier et al. | Aug 2019 | B1 |
10391492 | Handique et al. | Aug 2019 | B2 |
10391493 | Handique et al. | Aug 2019 | B2 |
10401373 | Holmes et al. | Sep 2019 | B1 |
10408736 | Handique | Sep 2019 | B1 |
10533152 | Belgrader et al. | Jan 2020 | B1 |
10718007 | Handique et al. | Jul 2020 | B2 |
20020009759 | Terstappen et al. | Jan 2002 | A1 |
20020028431 | Julien | Mar 2002 | A1 |
20020036142 | Gascoyne et al. | Mar 2002 | A1 |
20020036823 | Shimada et al. | Mar 2002 | A1 |
20020098535 | Wang et al. | Jul 2002 | A1 |
20020109838 | Columbus | Aug 2002 | A1 |
20020119482 | Nelson et al. | Aug 2002 | A1 |
20020192808 | Gambini et al. | Dec 2002 | A1 |
20030096277 | Chen | May 2003 | A1 |
20030103662 | Finkbeiner | Jun 2003 | A1 |
20030129676 | Terstappen et al. | Jul 2003 | A1 |
20030138941 | Gong et al. | Jul 2003 | A1 |
20040029241 | Hahn et al. | Feb 2004 | A1 |
20040106130 | Besemer et al. | Jun 2004 | A1 |
20040109793 | McNeely et al. | Jun 2004 | A1 |
20040160599 | Hamamatsu et al. | Aug 2004 | A1 |
20040191891 | Tsinberg et al. | Sep 2004 | A1 |
20040218472 | Narayanaswami et al. | Nov 2004 | A1 |
20040229349 | Daridon | Nov 2004 | A1 |
20040239922 | Modlin et al. | Dec 2004 | A1 |
20040248318 | Weinberger et al. | Dec 2004 | A1 |
20050001176 | Loney et al. | Jan 2005 | A1 |
20050014201 | Deuthsch | Jan 2005 | A1 |
20050037343 | Fagnani et al. | Feb 2005 | A1 |
20050042685 | Albert et al. | Feb 2005 | A1 |
20050063863 | Columbus | Mar 2005 | A1 |
20050095582 | Gillim-Ross et al. | May 2005 | A1 |
20050105172 | Hasegawa et al. | May 2005 | A1 |
20050112589 | Hahn et al. | May 2005 | A1 |
20050118640 | Kureshy et al. | Jun 2005 | A1 |
20050123445 | Blecka et al. | Jun 2005 | A1 |
20050158804 | Yao et al. | Jul 2005 | A1 |
20050164236 | Su et al. | Jul 2005 | A1 |
20050181463 | Rao et al. | Aug 2005 | A1 |
20050214173 | Facer et al. | Sep 2005 | A1 |
20050265815 | Rodi | Dec 2005 | A1 |
20050277125 | Benn et al. | Dec 2005 | A1 |
20060037915 | Strand et al. | Feb 2006 | A1 |
20060040274 | Tsinberg | Feb 2006 | A1 |
20060040407 | Falcovitz-Gerassi et al. | Feb 2006 | A1 |
20060050142 | Scott et al. | Mar 2006 | A1 |
20060115380 | Kagan et al. | Jun 2006 | A1 |
20060128006 | Gerhardt et al. | Jun 2006 | A1 |
20060141045 | Bhatt et al. | Jun 2006 | A1 |
20060147959 | Bell et al. | Jul 2006 | A1 |
20060160243 | Tang et al. | Jul 2006 | A1 |
20060257992 | McDevitt et al. | Nov 2006 | A1 |
20060263250 | Blouin et al. | Nov 2006 | A1 |
20070025882 | Zuppiger et al. | Feb 2007 | A1 |
20070026381 | Huang et al. | Feb 2007 | A1 |
20070111302 | Handique et al. | May 2007 | A1 |
20070154960 | Connelly et al. | Jul 2007 | A1 |
20070161051 | Tsinberg et al. | Jul 2007 | A1 |
20070172903 | Toner et al. | Jul 2007 | A1 |
20070238089 | Rosenthal et al. | Oct 2007 | A1 |
20070243523 | Ionescu-Zanetti et al. | Oct 2007 | A1 |
20070252265 | Sander | Nov 2007 | A1 |
20070264675 | Toner et al. | Nov 2007 | A1 |
20070264705 | Dodgson | Nov 2007 | A1 |
20070275418 | Hollmann et al. | Nov 2007 | A1 |
20080003224 | Fong et al. | Jan 2008 | A1 |
20080014589 | Link et al. | Jan 2008 | A1 |
20080020453 | Ehben et al. | Jan 2008 | A1 |
20080038231 | Rodgerson et al. | Feb 2008 | A1 |
20080068588 | Hess et al. | Mar 2008 | A1 |
20080090239 | Shoemaker et al. | Apr 2008 | A1 |
20080096212 | Bell et al. | Apr 2008 | A1 |
20080113358 | Kapur et al. | May 2008 | A1 |
20080113906 | Ding et al. | May 2008 | A1 |
20080124726 | Monforte | May 2008 | A1 |
20080182273 | Hansen et al. | Jul 2008 | A1 |
20080206751 | Squirrell et al. | Aug 2008 | A1 |
20080207615 | Bell et al. | Aug 2008 | A1 |
20080220422 | Shoemaker et al. | Sep 2008 | A1 |
20080234264 | Bell et al. | Sep 2008 | A1 |
20080240539 | George et al. | Oct 2008 | A1 |
20080248043 | Babcook et al. | Oct 2008 | A1 |
20080257735 | Jeon et al. | Oct 2008 | A1 |
20080317325 | Ortyn et al. | Dec 2008 | A1 |
20090014360 | Toner et al. | Jan 2009 | A1 |
20090061450 | Hunter | Mar 2009 | A1 |
20090075361 | DeLouise et al. | Mar 2009 | A1 |
20090081773 | Kaufman | Mar 2009 | A1 |
20090141593 | Taha | Jun 2009 | A1 |
20090153844 | Peter et al. | Jun 2009 | A1 |
20090158823 | Kaduchak et al. | Jun 2009 | A1 |
20090162853 | Clark et al. | Jun 2009 | A1 |
20090215088 | Forsyth et al. | Aug 2009 | A1 |
20090220979 | Davis et al. | Sep 2009 | A1 |
20090258383 | Kovac et al. | Oct 2009 | A1 |
20090317836 | Kuhn et al. | Dec 2009 | A1 |
20100120077 | Daridon | May 2010 | A1 |
20100127168 | Khursheed | May 2010 | A1 |
20100210009 | Willson et al. | Aug 2010 | A1 |
20100227387 | Safar et al. | Sep 2010 | A1 |
20100232675 | Ortyn et al. | Sep 2010 | A1 |
20100233693 | Kopf-Sill et al. | Sep 2010 | A1 |
20100255471 | Clarke et al. | Oct 2010 | A1 |
20100261179 | Betley et al. | Oct 2010 | A1 |
20100291584 | Tseng et al. | Nov 2010 | A1 |
20100304485 | Karnik et al. | Dec 2010 | A1 |
20100304978 | Robbins et al. | Dec 2010 | A1 |
20110003380 | Miltenyi et al. | Jan 2011 | A1 |
20110005932 | Jovanovich et al. | Jan 2011 | A1 |
20110030808 | Chiou et al. | Feb 2011 | A1 |
20110045994 | Voldman et al. | Feb 2011 | A1 |
20110053151 | Hansen et al. | Mar 2011 | A1 |
20110053152 | Goldkorn et al. | Mar 2011 | A1 |
20110104718 | Rao et al. | May 2011 | A1 |
20110117634 | Halamish et al. | May 2011 | A1 |
20110143964 | Zhou et al. | Jun 2011 | A1 |
20110220567 | Kreuwel et al. | Sep 2011 | A1 |
20110227558 | Mannion et al. | Sep 2011 | A1 |
20110236904 | Hauch et al. | Sep 2011 | A1 |
20110280467 | George et al. | Nov 2011 | A1 |
20120021456 | Levine et al. | Jan 2012 | A1 |
20120071355 | Cooney | Mar 2012 | A9 |
20120071643 | Helfer et al. | Mar 2012 | A1 |
20120129190 | Chiu et al. | May 2012 | A1 |
20120152369 | Hiddessen et al. | Jun 2012 | A1 |
20120156675 | Lueerssen et al. | Jun 2012 | A1 |
20120164679 | Vrouwe et al. | Jun 2012 | A1 |
20120194805 | Ness et al. | Aug 2012 | A1 |
20120270310 | Spence et al. | Oct 2012 | A1 |
20120309104 | Uematsu et al. | Dec 2012 | A1 |
20120316074 | Saxonov | Dec 2012 | A1 |
20130116102 | Hansen | May 2013 | A1 |
20130130376 | Serobyan et al. | May 2013 | A1 |
20130171628 | Di et al. | Jul 2013 | A1 |
20130171728 | Simard | Jul 2013 | A1 |
20130190212 | Handique et al. | Jul 2013 | A1 |
20130203634 | Jovanovich et al. | Aug 2013 | A1 |
20130210127 | Williams et al. | Aug 2013 | A1 |
20130230860 | Park et al. | Sep 2013 | A1 |
20130244906 | Collins | Sep 2013 | A1 |
20130259635 | Maslana et al. | Oct 2013 | A1 |
20130287645 | Shaikh et al. | Oct 2013 | A1 |
20140030717 | Zhong et al. | Jan 2014 | A1 |
20140051595 | So | Feb 2014 | A1 |
20140087370 | Maeshima | Mar 2014 | A1 |
20140155295 | Hindson et al. | Jun 2014 | A1 |
20140161686 | Bort et al. | Jun 2014 | A1 |
20140173443 | Hawkins et al. | Jun 2014 | A1 |
20140212881 | Handique et al. | Jul 2014 | A1 |
20140213487 | Freudenthal et al. | Jul 2014 | A1 |
20140220617 | Yung et al. | Aug 2014 | A1 |
20140272965 | Handique et al. | Sep 2014 | A1 |
20140315237 | Masujima et al. | Oct 2014 | A1 |
20140329301 | Handique | Nov 2014 | A1 |
20140357511 | Handique et al. | Dec 2014 | A1 |
20140370612 | Bassler et al. | Dec 2014 | A1 |
20150011432 | Saxonov | Jan 2015 | A1 |
20150089359 | Brisebois | Mar 2015 | A1 |
20150093306 | Thorne et al. | Apr 2015 | A1 |
20150133319 | Fu et al. | May 2015 | A1 |
20150160135 | Tibbe et al. | Jun 2015 | A1 |
20150160931 | Glazer et al. | Jun 2015 | A1 |
20150204864 | Fan et al. | Jul 2015 | A1 |
20150253251 | McKee et al. | Sep 2015 | A1 |
20150299784 | Fan et al. | Oct 2015 | A1 |
20150376609 | Hindson et al. | Dec 2015 | A1 |
20160008814 | Handique et al. | Jan 2016 | A1 |
20160024572 | Shishkin et al. | Jan 2016 | A1 |
20160024761 | Korb | Jan 2016 | A1 |
20160053253 | Salathia et al. | Feb 2016 | A1 |
20160060621 | Agresti et al. | Mar 2016 | A1 |
20160108464 | Saxonov et al. | Apr 2016 | A1 |
20160130649 | Xie et al. | May 2016 | A1 |
20160199838 | Handique et al. | Jul 2016 | A1 |
20160209319 | Adalsteinsson et al. | Jul 2016 | A1 |
20160251714 | Conant et al. | Sep 2016 | A1 |
20160289669 | Fan et al. | Oct 2016 | A1 |
20160314242 | Schnall-Levin et al. | Oct 2016 | A1 |
20160367991 | Petersen et al. | Dec 2016 | A1 |
20170044525 | Kaper et al. | Feb 2017 | A1 |
20170073405 | Fuh et al. | Mar 2017 | A1 |
20170153219 | Handique et al. | Jun 2017 | A1 |
20170276682 | Park | Sep 2017 | A1 |
20170307502 | Mason et al. | Oct 2017 | A1 |
20170320038 | Husain et al. | Nov 2017 | A1 |
20170321252 | Hindson et al. | Nov 2017 | A1 |
20170335385 | Hindson et al. | Nov 2017 | A1 |
20170356027 | Hindson et al. | Dec 2017 | A1 |
20170370951 | Buffiere et al. | Dec 2017 | A1 |
20180030515 | Regev et al. | Feb 2018 | A1 |
20180037942 | Fu | Feb 2018 | A1 |
20180051321 | Hindson et al. | Feb 2018 | A1 |
20180080075 | Brenner et al. | Mar 2018 | A1 |
20180088112 | Fan et al. | Mar 2018 | A1 |
20180094298 | Hindson et al. | Apr 2018 | A1 |
20180094312 | Hindson et al. | Apr 2018 | A1 |
20180105808 | Mikkelsen et al. | Apr 2018 | A1 |
20180112266 | Hindson et al. | Apr 2018 | A1 |
20180127744 | Hu et al. | May 2018 | A1 |
20180127823 | Shekhar et al. | May 2018 | A1 |
20180272296 | Link et al. | Sep 2018 | A1 |
20180274027 | Hindson et al. | Sep 2018 | A1 |
20180282804 | Hindson et al. | Oct 2018 | A1 |
20180311636 | Jacobson et al. | Nov 2018 | A1 |
20190002814 | Masquelier et al. | Jan 2019 | A1 |
20190064168 | Handique et al. | Feb 2019 | A1 |
20190106739 | Terbrueggen | Apr 2019 | A1 |
20190153532 | Bharadwaj et al. | May 2019 | A1 |
20190241944 | Cater et al. | Aug 2019 | A1 |
20190285644 | Regev et al. | Sep 2019 | A1 |
20190338353 | Belgrader et al. | Nov 2019 | A1 |
20200209229 | Strong et al. | Jul 2020 | A1 |
20210252509 | Szita et al. | Aug 2021 | A1 |
Number | Date | Country |
---|---|---|
103894248 | Jul 2014 | CN |
103998394 | Aug 2014 | CN |
104789468 | Jul 2015 | CN |
2414548 | Feb 2012 | EP |
2414548 | Oct 2015 | EP |
2006098696 | Apr 2006 | JP |
2008136415 | Jun 2008 | JP |
2009195160 | Sep 2009 | JP |
2013541959 | Nov 2013 | JP |
2015527588 | Sep 2015 | JP |
2017063716 | Apr 2017 | JP |
2003035909 | May 2003 | WO |
2006098696 | Sep 2006 | WO |
2007044917 | Apr 2007 | WO |
2008061165 | May 2008 | WO |
2010120818 | Oct 2010 | WO |
2010142954 | Dec 2010 | WO |
2012057548 | May 2012 | WO |
2015133337 | Sep 2015 | WO |
2016151719 | Sep 2016 | WO |
2016162997 | Oct 2016 | WO |
2018013723 | Jan 2018 | WO |
2018058073 | Mar 2018 | WO |
2019165318 | Aug 2019 | WO |
Entry |
---|
Guo, P. et al. Microfluidic capture and release of bacteria in a conical nanopore array. Lab Chip. vol. 12, p. 558-561, 2012, published online Nov. 2011. |
Lindstrom, Sara (Royal Institute of Technology, Stockholm, Sweden, 2009, pp. 1-80). |
Seale, K. T. et al. “Mirrored pyramidal wells for simultaneous multiple vantage point microscopy.” Journal of Microscopy (2008) 2321-6. (Year: 2008). |
Sugio, Yoshihiro et al. “An agar-based on-chip neural-cell-cultivation system for stepwise control of network pattern generation during cell cultivation.” Sensors and Actuators B (2004) 99 156-162. (Year: 2004). |
Supplemental information from Tan et al. PNAS (2007) 104. (Year: 2007). |
Tan, Wei-Heang et al. “A trap-and-release integrated microfluidic system for dynamic microarray applications.” PNAS (2007) 104 1146-1151. (Year: 2007). |
“High-throughput imaging of a unique continuous flow microfluidics plate”, Scikon Innovation, Application Note, May 2016, https://www.moleculardevices.com/en/assets/app-note/dd/img/high-throughput-imaging-of-a-unique-continuous-flow-microfluidics-plate#gref. |
Chen, H., et al., “High-throughput, deterministic single cell trapping and long-term clonal cell culture in microfluidic devices”, Lab Chip. Feb. 21, 2015;15(4):1072-83. doi: 10.1039/c41c01176g. PMID: 25519528. |
Dura, Burak , et al., “scFTD-seq: freeze-thaw lysis based, portable approach toward highly distributed single-cell 3' mRNA profiling”, Nucleic Acids Research, 2019, vol. 47, No. 3, published online Nov. 20, 2018. |
Murphy, Travis W., et al., “Recent advances in the use of microfluidic technologies for signs;e cell analysis”, Analyst, Oct. 26, 2017, vol. 143, pp. 60-80. |
Sarkar, S. , et al., “Phenotypic drug profiling in droplet microfluidics for better targeting of drug-resistant tumors”, Lab on a chip., vol. 15, 23 (2015): 4441-50. doi:10.1039/c51c00923e. |
Stahl, Patrik L., et al., “Visualization and analysis of gene expression in tissue sections by spatial transcriptomics”, sciencemag.org, Jul. 2016, vol. 353, Issue 6294, pp. 78-82. |
Yeh, EC , et al., “Self-powered integrated microfluidic point-of-care low-cost enabling (SIMPLE) chip”, Sci Adv. Mar. 22, 2017;3(3):e1501645. doi:10.1126/sciadv.1501645. PMID: 28345028; PMCID: PM 5362183. |
Yuan, J. , et al., “An Automated Microwell Platform for Large-Scale Single Cell RNA-Seq.”, Sci Rep. Sep. 27, 2016;6:33883. doi: 10.1038/srep33883. PMID: 27670648; PMCID: PMC5037380. |
Shaminie, Jairaman , et al., “Improvement in the detection rate of t(14;18) translocation on paraffin-embedded tissue: combination approach using PCR and FISH”, Pathology, Oct. 2003, 35(5), pp. 414-421. |
Number | Date | Country | |
---|---|---|---|
20220187191 A1 | Jun 2022 | US |
Number | Date | Country | |
---|---|---|---|
61513785 | Aug 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17357287 | Jun 2021 | US |
Child | 17686229 | US | |
Parent | 17005159 | Aug 2020 | US |
Child | 17357287 | US | |
Parent | 16929427 | Jul 2020 | US |
Child | 17005159 | US | |
Parent | 16924492 | Jul 2020 | US |
Child | 16929427 | US | |
Parent | 16835603 | Mar 2020 | US |
Child | 16924492 | US | |
Parent | 16679639 | Nov 2019 | US |
Child | 16835603 | US | |
Parent | 16599704 | Oct 2019 | US |
Child | 16679639 | US | |
Parent | 16536155 | Aug 2019 | US |
Child | 16599704 | US | |
Parent | 16513580 | Jul 2019 | US |
Child | 16536155 | US | |
Parent | 16443140 | Jun 2019 | US |
Child | 16513580 | US | |
Parent | 16419254 | May 2019 | US |
Child | 16443140 | US | |
Parent | 16048104 | Jul 2018 | US |
Child | 16419254 | US | |
Parent | 15657553 | Jul 2017 | US |
Child | 16048104 | US | |
Parent | 15333420 | Oct 2016 | US |
Child | 15657553 | US | |
Parent | 14607918 | Jan 2015 | US |
Child | 15333420 | US | |
Parent | 13557510 | Jul 2012 | US |
Child | 14607918 | US |